Skip to main content

Table 3 The multiplicity of P. falciparu m infection and mean titer of anti-MSP1 antibodies, in subjects with antibodies that are either highly competitive (H) or poorly competitive (L) with the specific monoclonal antibodies.

From: Fine specificity of anti-MSP119 antibodies and multiplicity of Plasmodium falciparum Merozoite Surface Protein 1 types in individuals in Nigeria with sub-microscopic infection

aMonoclonal antibody

Number of subjects

cInfection

dAntibodies to rMSP1

 

Total n = 147

bInfected

M

S

MOI

Prevalence

P

Mean log titre

P

12.8

         

Poorly competitive (L)

100

99

50

49

1.73

78%

0.0006

2.3

0.0001

Highly competitive (H)

46

43

22

21

1.65

100%

 

3.2

 

12.10

         

Poorly competitive (L)

90

87

38*

49

0.86

77%

0.002

2.4

0.0001

Highly competitive (H)

57

56

35

21

0.98

96%

 

2.9

 

12.8 and 12.10

         

Poorly competitive (L)

75

74

33 **

41

1.62

73%

0.0007

2.3

0.0001

Highly competitive (H)

32

31

18

13

1.77

100%

 

3.2

 
  1. aMonoclonal antibody. mAb12.10 and mAb 12.8: L and H refer to the number of individuals with antibodies that are either poorly competitive or highly competitive with the monoclonal antibodies, respectively.
  2. bInfected: number of subjects positive by PCR.
  3. cInfection: M refers to individuals with two or more parasite clones, S refers to individuals with only one parasite type detected. MOI is the mean multiplicity of infection based on MSP1 block 2 alleles.
  4. dAntibodies to rMSP1: Prevalence is the number of subjects with antibodies against recombinant MSP1 as a percentage of the total.